Monoclonal antibodies are biologic drugs that are used to treat certain types of diseases such as arthritis, neurological diseases, heart diseases, inflammatory diseases, and many more. Since their introduction, the applications of monoclonal antibodies have expanded significantly. Monoclonal antibodies are now being developed for various neurological disease such as Alzheimer’s, multiple sclerosis, etc.  Currently approved monoclonal antibodies for neurological conditions include natalizumab, ocrelizumab, alemtuzumab, and many more. Rise in the burden of neurological diseases with high clinical unmet needs, strong clinical pipeline of neuronal monoclonal antibodies, and rise in awareness are factors that are driving the global neuronal monoclonal antibodies market.

It is estimated that Alzheimer’s disease and other dementias affect 47 million people worldwide, and the number is expected to increase threefold by 2050. However, disappointing results of promising pipeline molecule and high cost of therapy are anticipated to restrain the growth of the global neuronal monoclonal antibodies market. Moreover, a stringent regulatory scenario is likely to hamper the growth of the global neuronal monoclonal antibodies market during forecast period.

Request Brochure of Neuronal Monoclonal Antibodies Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=52410

The global neuronal monoclonal antibodies market can be segmented based on drug class, application, distribution channel, and region. In terms of drug class, the global neuronal monoclonal antibodies market can be classified into amyloid inhibitors, tau protein inhibitors, alpha-synuclein inhibitors, integrin antagonists, and others. Based on application, the global neuronal monoclonal antibodies market can be segmented into multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and others.

Major players operating in global neuronal monoclonal antibodies market are GlaxoSmithKline, Sanofi S. A., Biogen, Eli Lilly & Co. Bristol-Myers Squibb, and many more.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Leave a Reply

Your email address will not be published. Required fields are marked *